Thinly traded micro cap XBiotech (NASDAQ:XBIT) is up 16% premarket on modestly higher volume in reaction to its announcement that it has identified True Human antibodies, derived without modification from humans, that could potentially be used to treat COVID-19.
It discovered the antibodies in blood samples from people who recovered quickly from the respiratory infection provided by collaboration partner BioBridge Global who is participating in a program to provide convalescent plasma to treat severely ill COVID-19 patients.
Aimed at accelerating advancement of its pipeline, the company is expanding its existing manufacturing and research center in Austin, TX with a new 30K sq. ft. infectious disease R&D facility.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.